Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer - A population-based case control study from Finland

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1680-1688

  Koskela Niska, Virpi ^a   Pukkala, Eero ^b   Lyytinen, Heli ^a   Ylikorkala, Olavi ^a   Dyba, Tadeusz ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Finnish Cancer Registry   (Finland)

Author keywords

estrogen; histology; levonorgestrel intrauterine system; progestin; stage; tibolone

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; TIBOLONE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; FEMALE; FINLAND; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ESTROGEN; HISTOLOGY; LEVONORGESTREL INTRAUTERINE SYSTEM; PROGESTIN; STAGE; TIBOLONE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FINLAND; HUMANS; LEVONORGESTREL; MIDDLE AGED; NORPREGNENES; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGESTINS; REGISTRIES; RISK;

EID: 84880284647     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28167     Document Type: Article

References (38)

1. Greiser CM, Greiser EM, Doren M,. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 2007; 13: 453-63.
2. Pearce CL, Chung K, Pike MC, et al. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009; 115: 531-9.
3. Beral V, Million Women Study Collaborators, Bull D, et al. Ovarian cancer and hormone replacement therapy in the million women study. Lancet 2007; 369: 1703-10.
4. Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol 2012; 175: 1234-42.
5. Koskela-Niska V, Lyytinen H, Riska A, et al. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy-a nationwide study. Climacteric 2013; 16: 48-53.
6. Teppo L, Pukkala E, Lehtonen M,. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-9.
7. Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention, 3rd edn. New York: Oxford Press, 2006.
8. Lyytinen H, Pukkala E, Ylikorkala O,. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108: 1354-60.
9. Lyytinen H, Pukkala E, Ylikorkala O,. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113: 65-73.
10. Luoto R, Kaprio J, Uutela A,. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64-76.
11. Haney AF, Wild RA,. Options for hormone therapy in women who have had a hysterectomy. Menopause 2007; 14: 592-9.
12. Backman T, Huhtala S, Tuominen J, et al. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland. Eur J Contracept Reprod Health Care 2001; 6: 23-6.
13. Lyytinen HK, Dyba T, Ylikorkala O, et al. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2010; 126: 483-9.
14. Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. JAMA 2009; 302: 298-305.
15. Tsilidis KK, Allen NE, Key TJ, et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 2011; 22: 1075-84.
16. Salvador S, Gilks B, Kobel M, et al. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 2009; 19: 58-64.
17. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
18. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.
19. Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012; 13: 285-91.
20. Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144: 363-72.
21. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer 2012; 131: 938-48.
22. Soegaard M, Jensen A, Hogdall E, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1160-6.
23. Danforth KN, Tworoger SS, Hecht JL, et al. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007; 96: 151-6.
24. Vicus D, Finch A, Rosen B, et al. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol 2010; 118: 155-9.
25. Koskela-Niska V, Riska A, Lyytinen H, et al. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland. Gynecol Oncol 2012; 126: 241-4.
26. Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997; 79: 1944-50.
27. Rodriguez GC,. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998; 5: 271-6.
28. Hall JM,. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276: 36869-72.
29. Rahman KM, Sarkar FH,. Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells. J Steroid Biochem Mol Biol 2002; 80: 191-201.
30. Kurman RJ, Shih I,. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-43.
31. Jaakkola S, Lyytinen H, Pukkala E, et al. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009; 114: 1197-204.
32. Jaakkola S, Lyytinen HK, Dyba T, et al. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 2011; 128: 1644-51.
33. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
34. Lin KJ, Cheung WY, Lai JY, et al. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012; 130: 419-30.
35. Sarantaus L, Vahteristo P, Bloom E, et al. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001; 9: 424-30.
36. Auranen A, Pukkala E, Makinen J, et al. Cancer incidence in the first-degree relatives of ovarian cancer patients. Br J Cancer 1996; 74: 280-4.
37. Hammar M, Brynhildsen J, Dabrosin L, et al. Hormone replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 1996; 25: 193-9.
38. Kurian AW, Balise RR, McGuire V, et al. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005; 96: 520-30.